50 c by christmas, page-34

Greg-cannot understand your reasoning-the CAT split should have little effect on Invion with Photosoft.Under the previous arrangements Nadalol and Zafirlukast where heading nowhere due to the lack of funding if our Management had not secured the deals we now have in place ---you and I would be sitting back lamenting our losses.With the potential for Photosoft to change the way cancer is currently managed (and we should have a good indication in the first half of next year) the rewards will be massive in relation to the current share price! 

Nadalol and Zafirlukast under the new arrangements will obtain the funding that these two deserve and could dramatically change the lives of those who suffer from COPD and Cystic Fibrosis.